Immatics and Genmab to Combine Proprietary Technologies to Create Transformative Bispecific Therapies against Novel, Proprietary Tumor Targets
Moleculin announced that it has entered into a definitive agreement with institutional investors for a registered direct offering of securities with gross proceeds of approximately $2.3 million.
Moleculin announced it has received Polish National Office approval to begin its second Phase I/II clinical trial to study Annamycin for the treatment of relapsed or refractory acute myeloid leukemia.
LivaNova announced it received FDA 510(k) clearance for its MEMO 4D® semi-rigid mitral annuloplasty ring and confirmed the first implantation of the device.
LivaNova announced that William A. Kozy, retired Executive VP and CEO at Becton, Dickinson and Company, was elected by the Company’s shareholders to its board of directors.
Moleculin announced that it has entered into an agreement with the Jagiellonian University in Krakow, Poland, for the development of its STAT3 inhibitor, WP1732, for the treatment of ocular tumors.